# TriSalus Life Sciences Inc. (TLSI) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $5.00, market value $308 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). TriSalus Life Sciences Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 6.8×**. Each dollar of revenue is priced at 6.8×.
- **Price / book: 46.7×**. The shares trade at 46.7× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **Free-cash-flow yield: -7.6%**. Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Gross margin: 85.8%**. TriSalus Life Sciences Inc. keeps 85.8% of revenue after the direct cost of what it sells, the kind of margin that comes with software, brands or pricing power.
- **Operating margin: -67.7%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -86.9%**. The company reported a net loss over the last twelve months.
- **Return on equity: 115.8%**. A 115.8% return on equity is extremely high; check whether buybacks or debt have shrunk the equity base, which flatters the ratio.
- **Return on invested capital: 113.4%**. Return on all capital, debt included, is 113.4%: comfortably above what that capital costs.
- **Return on assets: -79.9%**. Each dollar of assets produces -79.9% of profit.

## Growth
- **Revenue growth (1 yr): 53.4%** (3-yr 53.9%/yr). Revenue grew 53.4% over the last year.
- **EPS growth (1 yr): -40.5%**. Earnings per share fell 40.5%, slower than revenue, so margins compressed.

## Financial health
- **Net debt / EBITDA: net cash**. TriSalus Life Sciences Inc. holds more cash than debt.
- **Altman Z-score: 0.09**. A Z-score of 0.09 is in the distress zone, a signal to examine the balance sheet closely.
- **Piotroski F-score: 3/9**. 3 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. TriSalus Life Sciences Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (4 analysts). 4 analysts cover TriSalus Life Sciences Inc.; the consensus is strong_buy, with an average price target of $10.00 (+100% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): -2.9%** (YTD -28.4%, 3-mo 57.7%). The shares are down 2.9% over twelve months including dividends.
- **From 52-week high: -37.1%** (127.3% above the low). Trading 37% below its 52-week high, deep in a drawdown.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 50**. An RSI of 50 is neutral.
- **Beta (1 yr): 1.19** (volatility 79%). Beta of 1.19 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=TLSI · Page: https://foliofundamentals.com/stocks/tlsi

Not investment advice.